Global Health Ltd. announces a new order win

Ghaziabad is too early for a company-guided gestation period or EBITDA target. The project currently has land secured for a 350+ bed hospital, but the detailed project plan remains under evaluation and is subject to Board approval and statutory approvals ^[1]. The closest company precedent suggests a roughly three-year construction cycle, followed by a separate occupancy and clinical-ramp period; the margin profile should initially resemble Noida’s ramp-up rather than the mature NCR portfolio.

Margin interpretation: Noida provides the clearest ramp benchmark: management was targeting progression toward about 20% EBITDA margin as the hospital approached profitability ^[4]. By contrast, the 24.1% Cluster 1 margin and 32% margin for Lucknow and Patna excluding Noida reflect facilities with greater utilisation and established clinical infrastructure ^[8]; they should not be treated as Ghaziabad’s initial margin target.

Analyst inference: Ghaziabad should be viewed as a Noida-like greenfield project, not as a brownfield capacity addition. Its total land-to-operation timeline could exceed the approximately three-year construction precedent because the company has not yet completed the detailed plan or approvals. The likely economic sequence is therefore: construction and commissioning first, sub-scale utilisation and staffing drag during ramp-up, and only later convergence toward the company’s mature-unit margin range. That conclusion is directional; no Ghaziabad commissioning date, ramp schedule, capex budget beyond the Rs 165.82 crore land acquisition, or EBITDA margin target has been disclosed ^[1].